Cyted Ltd

Cyted Health is a Cambridge-based biotechnology company specializing in gastrointestinal molecular diagnostics for early detection and monitoring of esophageal conditions. Founded in 2020 as a University of Cambridge spinout, the company develops non-endoscopic diagnostic platforms that enable minimally invasive cell collection from the esophagus. The flagship product, EndoSign®, is an FDA-cleared capsule sponge device that provides safe, accessible esophageal sampling with full tissue coverage, significantly improving patient comfort and access compared to traditional endoscopy. Cyted Health combines proprietary biomarker discovery with AI-driven diagnostic tools to detect Barrett's Esophagus, esophageal neoplasia, and early-stage esophageal cancer. The company has completed over 35,000 tests through the UK National Health Service and operates CLIA-accredited laboratories in both the UK and US, serving healthcare systems with evidence-based screening and surveillance solutions for gastrointestinal malignancy prevention.